Record NNP B-NP O
date NN I-NP O
: : O O
2062-05-30 CD O B-DATE
Internal NNP B-NP O
Medicine NNP I-NP O
BARTON NNP B-NP B-HOSPITAL
MEMORIAL NNP I-NP I-HOSPITAL
HOSPITAL NNP I-NP I-HOSPITAL
History NN B-NP O
of IN B-PP O
present JJ B-NP O
illness NN I-NP O
This DT B-NP O
was VBD B-VP O
a DT B-NP O
followup JJ I-NP O
visit NN I-NP O
for IN B-PP O
this DT B-NP O
28 CD I-NP B-AGE
-year-old JJ I-NP O
black JJ I-NP O
man NN I-NP O
with IN B-PP O
the DT B-NP O
medical JJ I-NP O
problems NNS I-NP O
of IN B-PP O
type NN B-NP O
1 CD I-NP O
diabetes NN I-NP O
mellitus NN I-NP O
, , O O
hypertension NN B-NP O
, , O O
thrombocytosis NN B-NP O
, , O O
and CC O O
chronic JJ B-NP O
renal JJ I-NP O
insufficiency NN I-NP O
. . O O
The DT B-NP O
patient JJ I-NP O
states NNS I-NP O
that IN B-PP O
since IN B-SBAR O
I PRP B-NP O
last RB B-ADVP O
saw VBD B-VP O
him PRP B-NP O
, , O O
he PRP B-NP O
is VBZ B-VP O
being VBG I-VP O
evaluated VBN I-VP O
further RB B-ADVP O
for IN B-PP O
renal JJ B-NP O
transplant NN I-NP O
. . O O
In IN B-PP O
addition NN B-NP O
, , O O
attempts NNS B-NP O
were VBD B-VP O
made VBN I-VP O
to TO B-VP O
place VB I-VP O
an DT B-NP O
AV NNP I-NP O
fistula NN I-NP O
for IN B-PP O
dialysis NN B-NP O
in IN B-PP O
his PRP$ B-NP O
right JJ I-NP O
arm NN I-NP O
and CC O O
this DT B-NP O
did VBD B-VP O
not RB I-VP O
work VB I-VP O
out RP B-NP O
. . O O
Given VBN B-VP O
that IN B-PP O
this DT B-NP O
one NN I-NP O
did VBD B-VP O
not RB I-VP O
work VB I-VP O
out RP B-ADVP O
, , O O
a DT B-NP O
decision NN I-NP O
was VBD B-VP O
made VBN I-VP O
to TO I-VP O
wait VB I-VP O
to TO I-VP O
see VB I-VP O
if IN B-SBAR O
there EX B-NP O
was VBD B-VP O
a DT B-NP O
transplant NN I-NP O
candidate NN I-NP O
for IN B-PP O
him PRP B-NP O
to TO B-VP O
get VB I-VP O
a DT B-NP O
renal JJ I-NP O
transplant NN I-NP O
rather RB B-PP O
than IN I-PP O
put VB B-VP O
all DT B-NP O
of IN B-PP O
the DT B-NP O
pieces NNS I-NP O
in IN B-PP O
place NN B-NP O
for IN B-PP O
hemodialysis NN B-NP O
if IN B-PP O
in IN B-PP O
fact NN B-NP O
he PRP B-NP O
would MD B-VP O
need VB I-VP O
it PRP B-NP O
. . O O
Most RBS B-ADVP O
recently RB I-ADVP O
, , O O
the DT B-NP O
patient NN I-NP O
's POS B-NP O
creatinine NN I-NP O
was VBD B-VP O
6.4 CD B-NP O
and CC O O
his PRP$ B-NP O
BUN NNP I-NP O
was VBD B-VP O
46 CD B-NP O
two CD I-NP O
weeks NNS I-NP O
ago RB B-ADVP O
. . O O
Major NNP B-NP O
Problems NNS I-NP O
Diabetes NNP B-NP O
mellitus NN I-NP O
Type NNP B-NP O
1 CD I-NP O
diabetes NN I-NP O
mellitus NN I-NP O
. . O O
The DT B-NP O
patient NN I-NP O
's POS B-NP O
diabetes NN I-NP O
is VBZ B-VP O
currently RB I-VP O
well RB I-VP O
controlled VBN I-VP O
on IN B-PP O
his PRP$ B-NP O
current JJ I-NP O
regimen NNS I-NP O
of IN B-PP O
NPH NNP B-NP O
and CC O O
Regular NNP B-NP O
Insulin NNP I-NP O
. . O O
Most RBS B-ADVP O
recently RB I-ADVP O
, , O O
his PRP$ B-NP O
hemoglobin NN I-NP O
A1c . O O
was VBD B-VP O
6.6 CD B-NP O
on IN B-PP O
02/27/2062 NN B-NP B-DATE
. . O O
The DT B-NP O
patient NN I-NP O
states NNS I-NP O
that IN B-PP O
all DT B-NP O
of IN B-PP O
his PRP$ B-NP O
fingersticks NNS I-NP O
at IN B-PP O
home NN B-NP O
have VBP B-VP O
been VBN I-VP O
consistently RB B-ADVP O
between IN B-PP O
70 CD B-NP O
and CC I-NP O
110 CD I-NP O
. . O O
Chronic NNP B-NP O
renal NNP I-NP O
insufficiency NN I-NP O
The DT B-NP O
patient NN I-NP O
is VBZ B-VP O
being VBG I-VP O
evaluated VBN I-VP O
for IN B-PP O
renal JJ B-NP O
transplant NN I-NP O
and CC O O
possible JJ B-NP O
candidate NN I-NP O
that IN B-PP O
his PRP$ B-NP O
family NN I-NP O
members NNS I-NP O
and CC I-NP O
friends NNS I-NP O
will MD B-VP O
be VB I-VP O
tested VBN I-VP O
to TO B-VP O
see VB I-VP O
whether IN B-SBAR O
there EX B-NP O
are VBP B-VP O
a DT B-NP O
match NN I-NP O
shortly RB B-ADVP O
. . O O
Hypertension NN B-NP O
The DT B-NP O
patient NN I-NP O
is VBZ B-VP O
on IN B-PP O
a DT B-NP O
tremendous JJ I-NP O
amount NN I-NP O
of IN B-PP O
medication NN B-NP O
to TO B-VP O
treat VB I-VP O
his PRP$ B-NP O
hypertension NN I-NP O
. . O O
Currently RB B-ADVP O
, , O O
he PRP B-NP O
is VBZ B-VP O
on IN B-PP O
labetalol NN B-NP O
600 CD I-NP O
mg JJ I-NP O
PO NNP I-NP O
BID NNP I-NP O
, , O O
furosemide RB B-ADVP O
20 CD B-NP O
mg NN I-NP O
PO NN I-NP O
QD NNP I-NP O
, , O O
clonidine JJ B-NP O
0.3 CD I-NP O
mg NN I-NP O
PO NNP I-NP O
QHS NNP I-NP O
, , O O
lisinopril NN B-NP O
40 CD I-NP O
mg NN I-NP O
PO NNP I-NP O
QD NNP I-NP O
, , O O
and CC O O
nifedipine JJ B-NP O
XL NNP I-NP O
90 CD I-NP O
mg NN I-NP O
PO NNP I-NP O
QHS. NNP I-NP O
BHypertension NNP I-NP O
is VBZ B-VP O
currently RB I-VP O
well RB I-VP O
controlled VBN I-VP O
on IN B-PP O
this DT B-NP O
regimen NN I-NP O
. . O O
Erectile NNP B-NP O
dysfunction NN I-NP O
The DT B-NP O
patient NN I-NP O
was VBD B-VP O
experiencing VBG I-VP O
erectile IN B-PP O
dysfunction NN B-NP O
largely RB B-ADVP O
on IN B-PP O
Toprol NNP B-NP O
. . O O
For IN B-PP O
this DT B-NP O
reason NN I-NP O
, , O O
the DT B-NP O
Toprol NNP I-NP O
was VBD B-VP O
discontinued VBN I-VP O
and CC O O
the DT B-NP O
patient NN I-NP O
is VBZ B-VP O
having VBG I-VP O
less JJR B-NP O
of IN B-PP O
a DT B-NP O
problem NN I-NP O
with IN B-PP O
this DT B-NP O
issue NN I-NP O
currently RB B-ADVP O
. . O O
Anemia NN B-NP O
The DT B-NP O
patient NN I-NP O
's POS B-NP O
anemia NN I-NP O
is VBZ B-VP O
due JJ B-ADJP O
to TO B-PP O
multiple JJ B-NP O
different JJ I-NP O
factors NNS I-NP O
. . O O
He PRP B-NP O
has VBZ B-VP O
recently RB I-VP O
been VBN I-VP O
started VBN I-VP O
on IN B-PP O
erythropoietin NN B-NP O
, , O O
which WDT B-NP O
he PRP B-NP O
is VBZ B-VP O
getting VBG I-VP O
via IN B-PP O
injection NN B-NP O
in IN B-PP O
the DT B-NP O
Internal NNP I-NP O
Medicine NNP I-NP O
three CD I-NP O
times NNS I-NP O
a DT B-NP O
week NN I-NP O
. . O O
Most RBS B-ADVP O
recently RB I-ADVP O
, , O O
his PRP$ B-NP O
hematocrit NN I-NP O
was VBD B-VP O
29.4 CD B-NP O
% NN I-NP O
two CD B-NP O
weeks NNS I-NP O
ago RB B-ADVP O
. . O O
Thrombocytosis . O O
The DT B-NP O
patient NN I-NP O
is VBZ B-VP O
on IN B-PP O
Hydria NNP B-NP O
500 CD I-NP O
mg NN I-NP O
PO NNP I-NP O
QD NNP I-NP O
for IN B-PP O
this DT B-NP O
problem NN I-NP O
and CC O O
he PRP B-NP O
is VBZ B-VP O
being VBG I-VP O
followed VBN I-VP O
by IN B-PP O
Hematology NNP B-NP O
. . O O
Hyperlipidemia NNP B-NP O
The DT B-NP O
patient NN I-NP O
's POS B-NP O
hyperlipidemia NN I-NP O
is VBZ B-VP O
new JJ B-ADJP O
. . O O
Most RBS B-ADVP O
recently RB I-ADVP O
, , O O
his PRP$ B-NP O
lipids NNS I-NP O
were VBD B-VP O
done VBN I-VP O
on IN B-PP O
02/27/2062 CD B-NP B-DATE
and CC O O
at IN B-PP O
that DT B-NP O
time NN I-NP O
his PRP$ B-NP O
total JJ I-NP O
cholesterol NN I-NP O
was VBD B-VP O
294 CD B-NP O
and CC O O
his PRP$ B-NP O
LDL NNP I-NP O
was VBD B-VP O
209 CD B-NP O
. . O O
This DT B-NP O
is VBZ B-VP O
a DT B-NP O
new JJ I-NP O
problem NN I-NP O
for IN B-PP O
the DT B-NP O
patient NN I-NP O
, , O O
given VBN B-VP O
that IN B-PP O
his PRP$ B-NP O
lipids NNS I-NP O
were VBD B-VP O
fairly RB B-ADJP O
normal JJ I-ADJP O
six CD B-NP O
months NNS I-NP O
ago RB B-ADVP O
. . B-VP O
Given VBN I-VP O
this DT B-NP O
, , O O
the DT B-NP O
patient NN I-NP O
was VBD B-VP O
started VBN I-VP O
on IN B-PP O
Lipitor NNP B-NP O
20 CD I-NP O
mg , O O
PO NNP B-NP O
QD NNP I-NP O
for IN B-PP O
hyperlipidemia NN B-NP O
. . O O
We PRP B-NP O
will MD B-VP O
repeat VB I-VP O
his PRP$ B-NP O
lipid JJ I-NP O
panel NN I-NP O
at IN B-PP O
the DT B-NP O
time NN I-NP O
of IN B-PP O
his PRP$ B-NP O
next JJ I-NP O
visit NN I-NP O
in IN B-PP O
eight CD B-NP O
weeks NNS I-NP O
. . O O
Active NNP B-NP O
Medications NNPS I-NP O
aspirin NN B-NP O
81mg CD I-NP O
po NN I-NP O
qd NN I-NP O
clonidine NN B-NP O
0.3mg CD I-NP O
po NN I-NP O
1 CD I-NP O
tabs NN I-NP O
po NN I-NP O
q NN I-NP O
pm NN I-NP O
furosemide JJ B-NP O
20 CD I-NP O
mg NN I-NP O
po NN I-NP O
qd . O O
Humulin NNP B-NP O
n RB I-NP O
40 CD I-NP O
units NNS I-NP O
qam VBP B-VP O
sc NN B-NP O
36 CD B-NP O
units NNS I-NP O
qpm VBP B-VP O
take VB I-VP O
30-60min NN B-NP O
before IN B-PP O
a DT B-NP O
meal NN I-NP O
or CC I-NP O
hs NNS I-NP O
Hydrea NNP B-NP O
500mg CD I-NP O
po NN I-NP O
bid NN I-NP O
Insulin NNP B-NP O
syringes NNS I-NP O
(u VBD B-VP O
100 CD B-NP O
) -RRB- O O
labetalol NN B-NP O
HCl RB B-ADVP O
tablets VBZ B-VP O
600 CD B-NP O
mg JJ I-NP O
po NN I-NP O
bid NN I-NP O
Lancets NNS B-NP O
Lipitor NNP B-NP O
20mg CD I-NP O
po NN I-NP O
qd NN I-NP O
lisinopril NN B-NP O
40mg CD I-NP O
po NN I-NP O
qd NN I-NP O
Nexium NNP B-NP O
40mg CD I-NP O
po NN I-NP O
bid NN I-NP O
take VBP B-VP O
1h JJ B-ADJP O
before IN B-SBAR O
meal NN B-NP O
nifedipine JJ B-NP O
xl JJ I-NP O
90mg JJ I-NP O
sr NN I-NP O
po NN I-NP O
qhs NNS I-NP O
do VBP B-VP O
not RB I-VP O
cut/crush/chew VB I-VP O
Onetouch DT B-NP O
test NN I-NP O
strips NNS I-NP O
potassium NN B-NP O
chloride NN I-NP O
10meq IN B-PP O
po NN B-NP O
qd CC O O
regular JJ B-NP O
insulin NN I-NP O
25 CD B-NP O
units NNS I-NP O
qam IN B-PP O
sc NN B-NP O
20 CD I-NP O
units NNS I-NP O
qpm IN B-PP O
give VBP B-NP O
30-60min CD I-NP O
before IN B-PP O
a DT B-NP O
meal NN I-NP O
Change NNP B-NP O
in IN B-PP O
therapies NNS B-NP O
and CC I-NP O
Renewals NNS I-NP O
Hydrea NNP B-NP O
500mg CD I-NP O
po NN I-NP O
bid NN I-NP O
QTY NNP B-NP O
:60 CD I-NP O
Refills NNP I-NP O
:5 CD I-NP O
Start NNP I-NP O
: : O O
10/16/2061 CD O B-DATE
Toprol NNP B-NP O
xl NNP I-NP O
100 CD I-NP O
mg JJ I-NP O
po NN I-NP O
bid NN I-NP O
QTY:30 IN B-PP O
Refills NNP B-NP O
:5 CD I-NP O
Start NNP I-NP O
: : O O
10/16/2061 CD B-NP B-DATE
End NN I-NP O
: : O O
5/30/2062 CD B-NP B-DATE
- : O O
Inactivated CC O O
furosemide JJ B-NP O
20 CD I-NP O
mg NN I-NP O
po NN I-NP O
qd VBD B-VP O
QTY:30 CD B-NP O
Refills NNS I-NP O
:5 IN B-PP O
Start NNP B-NP O
: : O O
10/16/2061 CD O B-DATE
labetalol NN B-NP O
HCl RB B-ADVP O
tablets VBZ B-VP O
600 CD B-NP O
mg JJ I-NP O
po NN I-NP O
bid NN I-NP O
QTY NNP B-NP O
:60 CD I-NP O
Refills NNP I-NP O
:5 CD I-NP O
Start NNP I-NP O
: : O O
05/30/2062 CD O B-DATE
Lipitor NNP B-NP O
20mg CD I-NP O
po NN I-NP O
qd VBD B-VP O
QTY:30 CD B-NP O
Refills NNS I-NP O
:5 IN B-PP O
Start NNP B-NP O
: : O O
05/30/2062 CD O B-DATE
Physical JJ B-NP O
examination NN I-NP O
Blood NN B-NP O
pressure NN I-NP O
120/88 CD O O
Weight NNP B-NP O
215 CD I-NP O
pounds NNS I-NP O
General NNP B-NP O
appearance NN I-NP O
This DT B-NP O
was VBD B-VP O
a DT B-NP O
well-developed JJ I-NP O
, , I-NP O
well-nourished JJ I-NP O
black JJ I-NP O
man NN I-NP O
, , O O
in IN B-PP O
no DT B-NP O
distress NN I-NP O
Chest NNP B-NP O
Lungs NNP I-NP O
were VBD B-VP O
clear JJ B-ADJP O
throughout IN B-PP O
to TO B-NP O
AandP NNP O O
Cor NNP B-NP O
Regular JJ I-NP O
rate NN I-NP O
and CC I-NP O
rhythm NN I-NP O
with IN B-PP O
no DT B-NP O
murmurs NNS I-NP O
, , O O
rubs NNS B-NP O
, , O O
or CC O O
gallops NNS B-NP O
Selected NNP B-NP O
recent JJ I-NP O
labs NNS I-NP O
Fingerstick NNP B-NP O
blood NN I-NP O
sugar NN I-NP O
75 CD I-NP O
. . O O
Disposition NN B-NP O
The DT B-NP O
patient NN I-NP O
will MD B-VP O
follow VB I-VP O
up RP B-PRT O
with IN B-NP O
me PRP B-NP O
again RB B-ADVP O
in IN B-PP O
six CD B-NP O
to TO I-NP O
eight CD I-NP O
weeks NNS I-NP O
. . O O
Note VB B-VP O
transcribed VBN I-VP O
by IN B-PP O
outside JJ B-NP O
service NN I-NP O
Transcription NNP B-NP O
errors NNS I-NP O
may MD B-VP O
be VB I-VP O
present JJ B-ADJP O
. . O O
Signed VBN B-VP O
electronically RB B-ADVP O
by IN B-PP O
Ali NNP B-NP I-DOCTOR
, , O I-DOCTOR
Felicia NNP B-NP I-DOCTOR
on IN B-PP O
Jun NNP B-NP B-DATE
6 CD I-NP I-DATE
, , I-NP I-DATE
2062 CD O I-DATE
